Holzer Holzer & Fistel, LLC is investigating potential shareholder claims on behalf of investors in Orthofix International N.V., AdCare Health Systems, Inc. and TearLab Corporation. The firm is investigating whether the companies complied with federal securities laws in issuing certain public statements. Investors who purchased stock in any of these companies during the relevant time periods identified below that would like to discuss their legal rights are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel, Jr., Esq. ( email@example.com) or Marshall P. Dees, Esq. ( firstname.lastname@example.org) via email or via toll-free telephone at (888) 508-6832. Orthofix International N.V. On July 29, 2013, Orthofix International (NASDAQ: OFIX) announced that it would be unable to file its quarterly report on Form 10-Q for the quarter ended June 30, 2013 by the deadline of August 9, 2013. The company announced that additional time was needed for its Audit Committee to review revenue recognition issues for prior periods. The price of Orthofix shares fell significantly on the news. The firm’s investigation seeks to determine if statements made between July 26, 2012 and July 29, 2013 relating to the company’s business, prospects and results were misleading to investors at the time they were made. AdCare Health Systems, Inc. On March 13, 2013, AdCare Health Systems (NYSE: ADK) announced that investors should not rely on its previously issued financial statements for the quarters ended March 31, 2012, June 30, 2012 and September 30, 2012 due to issues relating to the company’s ability to properly account for certain complex transactions. It also announced that the Audit Committee identified material weaknesses with its internal accounting controls. On April 15, 2013, AdCare further announced the resignation of its Chief Financial Officer and stated that it would be delaying the filing of its annual Form 10-K. AdCare’s stock price has declined dramatically in the wake of these announcements and the firm’s investigation seeks to determine if the Company complied with the federal securities laws between January 1, 2012 and July 8, 2013.
TearLab CorporationOn August 1, 2013, TearLab Corporation’s (NASDAQ: TEAR) stock price fell following a report from Streetsweeper.com that claimed a survey of doctors listed as providers of TearLab’s diagnostic test for dry eyes on its website had discontinued using the company’s product. The firm is investigating whether certain officers and/or directors of TearLab complied with the federal securities laws in connection with the company’s public statements made between July 24, 2012 and July 23, 2013 relating to its business and operations. Investors interested in additional information should contact Holzer Holzer & Fistel, LLC. The firm dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.